October 28, 2025
1 min read

Regeneron reports another manufacturing-related rejection for Eylea HD, but says help is on the way

The FDA has issued another complete response letter to Regeneron over its high-dose Eylea due to unresolved issues at a Novo Nordisk manufacturing plant. The company, however, is making progress in lining up alternate manufacturing help.

Leave a Reply

Your email address will not be published.

Previous Story

Eye Scans Might Help Determine Heart Health Risk, Experts Say

Next Story

Vaccinations go up when exemptions go down, research finds

Previous Story

Eye Scans Might Help Determine Heart Health Risk, Experts Say

Next Story

Vaccinations go up when exemptions go down, research finds

Latest from Blog

Go toTop